Catalyst Pharmaceuticals secures Firdapse patent protection through 2035 in Hetero settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) and its licensor, SERB, have successfully resolved their patent litigation with Hetero and its affiliates regarding Firdapse (amifampridine) 10 mg tablets.










